Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Exclusion Criteria

• •1. Having difficulty swallowing or malabsorption syndrome or any other uncontrolled gastrointestinal disease (such as nausea, diarrhea, or vomiting), having undergone gastrectomy or gastric banding surgery, etc
• •2. Symptomatic or active central nervous system tumor metastasis
• •3. Previously or simultaneously suffering from other malignant tumors
• •4. Spinal cord compression that cannot be cured by surgery and/or radiotherapy
• •5. Accompanied by uncontrolled tumor related pain
• •6. Plan to receive any other anti-tumor treatment during this trial period
• •7. Receive other anti-tumor treatments within 4 weeks before the first medication
• •8. Having undergone major surgeries other than diagnosis or biopsy within 28 days prior to the first administration
• •9. Currently participating in other clinical studies or taking medication for the first time less than 4 weeks after the end of the previous clinical study
• •10. Moderate to severe pleural effusion with clinical symptoms
• •11. Individuals with active pulmonary tuberculosis infection within one year prior to the first use of medication
• •12. Subjects who have experienced severe infections within 30 days prior to their first medication use
• •13. Administer attenuated live vaccine within 30 days before the first use of medication.
• •14. History of immunodeficiency
• •15. Suffering from poorly controlled or severe cardiovascular and cerebrovascular diseases
• •16. History of interstitial pneumonia/non infectious pneumonia requiring hormone therapy in the past
• •17. AE caused by previous anti-tumor treatment has not recovered to CTCAE v5.0 level evaluation ≤ 1
• •18. Untreated active hepatitis
• •19. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
• •20. There are other serious physical or mental illnesses or laboratory abnormalities present